Education
About Us
Working with TipRanks
Follow Us
Edap Tms S.A. (EDAP)
NASDAQ:EDAP
EDAP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.26 - $7.40
Previous CloseN/A
Volume29.75K
Average Volume (3M)200.63K
Market Cap
$54.97M
Enterprise Value$66.11M
Total Cash (Recent Filing)€7.37M
Total Debt (Recent Filing)€14.38M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
May 14, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding37,103,780
10 Day Avg. Volume74,502
30 Day Avg. Volume200,634
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.80
Price to Cash Flow (P/CF)-4.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.50Price Target Upside331.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
EDAP TMS News
PremiumCompany Announcements
EDAP TMS S.A. Earnings Call Highlights HIFU Growth
PremiumCompany Announcements
EDAP TMS Reports Record HIFU Revenue Growth---
Bulls Say, Bears Say
Bulls Say
Market ExpansionExpansion of indications could lay path for long-term growth.
Revenue GrowthEDAP reported HIFU-related revenue of €4.5M in 3Q24, a 50% YoY increase from €3.0M in 3Q23.
Strategic FocusEDAP's plan to increase focus on higher-growth and -margin HIFU business should support consolidated sales growth and margin longer-term.
Bears Say
Competitive And Financial RisksThere is a potential need for capital, risk from intensifying prostate cancer tissue ablation competition, and risk from EU tariffs.
Rating DowngradeAnalyst lowers the rating from Buy to Hold, seeing downside to consensus estimates.
Regulatory RisksAnalyst does not incorporate sales from endometriosis or BPH applications due to regulatory and timeline uncertainty.
---
Ownership Overview
19.70%
Insiders
1.49% Mutual Funds
0.04% Other Institutional Investors
78.77% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
EDAP FAQ
What was Edap Tms S.A.’s price range in the past 12 months?
Edap Tms S.A. lowest stock price was $1.26 and its highest was $7.40 in the past 12 months.
What is Edap Tms S.A.’s market cap?
Edap Tms S.A.’s market cap is $54.97M.
When is Edap Tms S.A.’s upcoming earnings report date?
Edap Tms S.A.’s upcoming earnings report date is May 14, 2025 which is in 19 days.
How were Edap Tms S.A.’s earnings last quarter?
Edap Tms S.A. released its earnings results on Mar 27, 2025. The company reported -$0.057 earnings per share for the quarter, beating the consensus estimate of -$0.115 by $0.058.
Is Edap Tms S.A. overvalued?
According to Wall Street analysts Edap Tms S.A.’s price is currently Undervalued.
Does Edap Tms S.A. pay dividends?
Edap Tms S.A. does not currently pay dividends.
What is Edap Tms S.A.’s EPS estimate?
Edap Tms S.A.’s EPS estimate is -0.17.
How many shares outstanding does Edap Tms S.A. have?
Edap Tms S.A. has 37,103,780 shares outstanding.
What happened to Edap Tms S.A.’s price movement after its last earnings report?
Edap Tms S.A. reported an EPS of -$0.057 in its last earnings report, beating expectations of -$0.115. Following the earnings report the stock price went up 8.293%.
Which hedge fund is a major shareholder of Edap Tms S.A.?
Currently, no hedge funds are holding shares in EDAP
---
EDAP TMS Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.50 (331.47% Upside)
$8.50 (331.47% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.00%
12-Months-Change
Fundamentals
Return on Equity
-51.63%
Trailing 12-Months
Asset Growth
-11.88%
Trailing 12-Months
Company Description
Edap Tms S.A.
EDAP TMS (EDAP) is a French company specializing in the development, manufacturing, and distribution of minimally invasive medical devices for urology. The company operates primarily in the medical technology sector, focusing on therapeutic ultrasound solutions. Its core products include the Focal One and Ablatherm devices, which are used for High-Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, as well as devices for lithotripsy and other urological conditions.
---
EDAP Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant growth and achievements in the HIFU segment, including record sales, procedure growth, and positive regulatory developments. However, the company faced challenges such as an operating loss and a decline in distribution revenue. The sentiment remains positive with strong future growth expectations in the HIFU business.Read More>---
EDAP Stock 12 Month Forecast
Average Price Target
$8.50
▲(331.47% Upside)
Technical Analysis
Best Analysts Covering EDAP
1 Year
1 Year Success Rate
1/12 ratings generated profit
1 Year Average Return
-38.13%
reiterated a buy rating 29 days ago
Copying Jason Bednar's trades and holding each position for 1 Year would result in 8.33% of your transactions generating a profit, with an average return of -38.13% per trade.
---